The simultaneous impacts of global trade shifts, U.S. tax reforms, and changing drug pricing policies have prompted life ...

Tom Wells at 4C Associates, explores the future of biologistics, or how the packaging, storage, and logistics for biologics ...

Strong IP keeps collaboration alive, allowing companies to attract capital, strike partnerships, and bring innovations to patients, according to legal experts at Ice Miller.

Royalty-bearing license agreements are a cornerstone of commercialization in the life sciences and technology industries. Companies often use them to expand their business into new markets while ...

Marc Tessier-Lavigne, Ph.D. (left) and Martin Makary, M.D. (right) The FDA must “cut the idle time” that exists within the agency to bring drugs to market faster, said Commissioner Martin Makary, M.D.

The well-worn adage “good companies are bought, not sold” suggests that top-tier businesses, especially in high-growth industries like life sciences, do not need to seek buyers; instead, buyers pursue ...

As a CEO and a member of the Biotech CEO Sisterhood, I see a disconnect in our industry. Women are driving breakthrough innovations, leading successful companies through crisis, and delivering results ...

Growing up on a commune, you learn from an early age that your primary function is to serve the community. Filling gaps isn’t optional — it’s expected. I become skilled at quickly diagnosing what is ...

Failure to comply with clinical trial disclosure regulations poses risks that extend far beyond potential fines or reputational damage for sponsors. In the context of mergers and acquisitions (M&A), ...

Clinical trials are built around time-sensitive, patient-centered moments, such as when a patient arrives for a visit or completes a key assessment. Yet too often, disconnected technologies and ...

On this week's Business of Biotech episode — the last of our four-part series focused on South Florida — we catch up with Rich Daly, CEO at Catalyst Pharmaceuticals, a member of Life Science Leader's ...

On this week's episode of the Business of Biotech, we're speaking with Bernard Ravina, M.D., CEO at Vima Therapeutics, a company that emerged from stealth in May with $60 million Series A financing to ...